Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

ISSN： 1479-6694

Source： Future Oncology, Vol.6, Iss.3, 2010-03, pp. : 419-428

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospects for Hypoxia-Activated Anticancer Drugs

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 5, 2004-09 ,pp. : 395-399

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Small Molecule Prodrugs for Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 3, 2014-03 ,pp. : 418-439

Bentham Science Publishers

Access to resources Recommend Favorite

Progress in Cancer Gene Therapy

By Kouraklis Gregory

Acta Oncologica, Vol. 38, Iss. 6, 1999-09 ,pp. : 675-683

Informa Healthcare

Access to resources Recommend Favorite

Tyrosinase Activated Melanoma Prodrugs

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 7, 2009-09 ,pp. : 717-727

Bentham Science Publishers

Access to resources Recommend Favorite

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

International Journal of Oncology, Vol. 42, Iss. 2, 2013-01 ,pp. : 373-383

Spandidos Publications

Access to resources Recommend Favorite